Aimmune Therapeutics (NASDAQ:AIMT) perks up 10% premarket on average volume in reaction to its announcement that Nestlé Health Science will invest an additional $200M in the company, raising its stake to $473M (25.6% stake).
Nestlé’s investment includes 1M common shares at
$31.97 and 525,634 shares of convertible stock (one for ten based on
certain conditions) at $319.675.
Closing date is February 7.
Separately, AIMT has in-licensed global rights to Xencor’s (NASDAQ:XNCR) humanized monoclonal antibody, XmAb7195, for the potential treatment of food allergies (renamed AIMab7195).
Under the terms of the agreement, it will pay XNCR
$5M upfront, up to $385M in milestones and high
single-digit-to-mid-teen royalties on net sales. It will also invest $5M
in XNCR stock.
https://seekingalpha.com/news/3538510-aimmune-up-10-premarket-on-increased-nestl-stake
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.